Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Core Viewpoint - Axsome Therapeutics is celebrating its achievements in the treatment of central nervous system (CNS) disorders by ringing the NASDAQ opening bell, highlighting its innovative pipeline and recent product launch [1][2]. Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on CNS conditions, aiming to address critical gaps in care with differentiated products [3]. - The company has an industry-leading neuroscience portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine [3]. - Axsome's late-stage development programs target a wide range of serious neurological and psychiatric conditions affecting over 150 million people in the U.S. [3]. Recent Developments - The opening bell ceremony coincides with Axsome's Frontiers in Brain Health R&D Day, showcasing its late-stage CNS product candidates and the recent availability of SYMBRAVO by prescription in the U.S. [2]. - The event emphasizes the company's commitment to improving the lives of patients with serious CNS conditions [2].